Dr. Boriana S. Kamenova

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of Hereditary Neuroblastoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Thomas Hogan is a Hematologist Oncology specialist and an Oncologist in Morgantown, West Virginia. Dr. Hogan is rated as a Distinguished provider by MediFind in the treatment of Hereditary Neuroblastoma. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Renal Cell Carcinoma (RCC).

Anwaar Saeed, MD, is an Associate Professor of Medicine and the Chief of the Gastrointestinal (GI) Medical Oncology Program at the University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), and UPMC Hillman Cancer Center. She also serves as the Vice Chair of the Colorectal Cancer Committee of the NSABP Foundation. Her research efforts are focused on immune modulatory approaches in patients with gastric & esophageal cancer, colon cancer and hepatocellular carcinoma as well as chemoprevention/ immunoprevention in the high-risk GI population. She has published more than 150 peer reviewed papers, posters and book chapters, and have led more than 40 clinical trials, focused on various immune modulatory regimens including but not limited to immune checkpoint inhibitor combinations with chemotherapy, other checkpoint inhibitors, antibody drug conjugates, bi-specific T cell engagers (BiTE), angiogenesis inhibitors, as well as immunotherapy combinations with regional approaches like stereotactic radiosurgery and intensity-modulated radiation therapy. She currently leads several investigator-initiated trials focused on novel targeted immunotherapy combinations including the ongoing phase I/II CAMILLA multicohort study looking at Cabozantinib plus Durvalumab with or without Tremelimumab in GI malignancies. Results from phase I/II part of the CAMILLA led to the development of the currently ongoing global pivotal trial, STELLAR 303, in patients with previously treated microsatellite stable colorectal cancer. She is also the study chair for a soon to open SWOG/intergroup NCI national trial (S2303) testing a novel chemo-immunotherapy regimen in patients with advanced gastric & esophageal adenocarcinoma. Dr. Saeed is rated as a Distinguished provider by MediFind in the treatment of Hereditary Neuroblastoma. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Stomach Cancer, Cataract Removal, and Gamma Knife Radiosurgery.